Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim
Executive Summary
Genentech’s last-ditch bid to retain Avastin’s metastatic breast cancer claim expands upon discussions at FDA’s June 28-29 hearing about targeted subpopulations and labeling revisions, but breaks little new ground.
You may also be interested in...
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
Peregrine Puts Positive Breast Cancer Trial Data Under Its Belt
Data for bavituximab in breast cancer merit further investigation, says company.